Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• SiewertJRSteinHJFeithMBruecherBLBartelsHFinkUHistologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western worldAnn Surg2001234336036911524589
   PubMed Web of Science ®Google Scholar
• IizukaTKakegawaTIdeHPhase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese esophageal oncology group trialJpn J Clin Oncol19922231721761518165
   PubMed Web of Science ®Google Scholar
• AlbertssonMJohanssonBFrieslandSPhase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancerMed Oncol200724440741217917090
   PubMed Web of Science ®Google Scholar
• PetraschSWeltAReinacherAGraevenUKönigMSchmiegelWChemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancerBr J Cancer19987845115149716036
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• WangHRyuJGandaraDA phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancerJ Thorac Oncol20072215315717410032
   PubMed Web of Science ®Google Scholar
• KimJYDoYRParkKUA multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancerCancer Chemother Pharmacol2010661313619763571
   PubMed Web of Science ®Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSV325 Study GroupPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• OvermanMJKazmiSMJhambJWeekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancerCancer201011661446145320108336
   PubMed Web of Science ®Google Scholar
• TebbuttNCCumminsMMSourjinaTAustralasian GastroIntestinal Trials GroupRandomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialBr J Cancer2010102347548120068567
   PubMed Web of Science ®Google Scholar
• GreenMRManikhasGMOrlovSAbraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancerAnn Oncol20061781263126816740598
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089
   PubMed Web of Science ®Google Scholar
• MontanaMDucrosCVerhaeghePTermeTVanellePRathelotPAlbumin-bound paclitaxel: the beneft of this new formulation in the treatment of various cancersJ Chemother2011232596621571619
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer III trialJ Clin Oncol200523317794780316172456
   PubMed Web of Science ®Google Scholar
• Von HoffDDRamanathanRKBoradMJGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trialJ Clin Oncol201129344548455421969517
   PubMed Web of Science ®Google Scholar
• SocinskiMAManikhasGMStroyakovskyDLA dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancerJ Thorac Oncol20105685286120521351
   PubMed Web of Science ®Google Scholar
• OkenMMCreechRHTormeyDCToxicity and response criteria of the Eastern Cooperative Oncology GroupAm J Clin Oncol1982566496557165009
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• National Cancer Institute: Common Terminology Criteria for Adverse Events version 3.0. (CTCAE)http://ctep.cancer.gov/reporting/ctc_v30.html
   Google Scholar
• National Comprehensive Cancer Network Guidelines in OncologyEsophageal cancer Available at: http://www.nccn.org
   Google Scholar
• HomsMYv d GaastASiersemaPDSteyerbergEWKuipersEJChemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junctionCochrane Database Syst Rev20064CD00406317054195
   PubMedGoogle Scholar
• SiewertJROttKAre squamous and adenocarcinomas of the esophagus the same disease?Semin Radiat Oncol2007171384417185196
   PubMed Web of Science ®Google Scholar
• DreilichMWandersABrattströmDHER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survivalDis Esophagus200619422423116866851
   PubMed Web of Science ®Google Scholar
• LiQQLiuMZHuYHLiuHHeZYLinHXDefinitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinomaDis Esophagus201023325325919732130
   PubMed Web of Science ®Google Scholar
• YunTHanJYLeeJSPhase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinomaBMC Cancer20111138521888637
   PubMed Web of Science ®Google Scholar
• TakahashiHArimuraYYamashitaKPhase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinomaJ Thorac Oncol20105112212819898259
   PubMed Web of Science ®Google Scholar
• CaoWXuCLouGA phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancerJpn J Clin Oncol200939958258719509000
   PubMed Web of Science ®Google Scholar
• GongYRenLZhouLPhase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinomaCancer Chemother Pharmacol200964232733319048253
   PubMed Web of Science ®Google Scholar
• ZhangXShenLLiJLiYLiJJinMA phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagusAm J Clin Oncol2008311293318376224
   PubMed Web of Science ®Google Scholar
• LaackEAndritzkyBDürkHDocetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot studyOnkologie2005281264765016330888
   PubMedGoogle Scholar
• LeeSParkYHKimKHThymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinomaBr J Cancer2010103684585120700125
   PubMed Web of Science ®Google Scholar
• HondaMMiuraAIzumiYDoxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinomaDis Esophagus201023864164520545978
   PubMed Web of Science ®Google Scholar
• LorenzenSSchusterTPorschenRCetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieAnn Oncol200920101667167319549707
   PubMed Web of Science ®Google Scholar
• QinTJAnGLZhaoXHCombined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancerWorld J Gastroenterol200915787187619230050
   PubMed Web of Science ®Google Scholar
• LeeJImYHChoEYA phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinomaCancer Chemother Pharmacol2008621778417762932
   PubMed Web of Science ®Google Scholar
• GradisharWJAlbumin-bound paclitaxel: a next-generation taxaneExpert Opin Pharmacother2006781041105316722814
   PubMed Web of Science ®Google Scholar
• DesaiNPTrieuVHwangLYWuRSoon-ShiongPGradisharWJImproved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC statusAnticancer Drugs200819989990918766004
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSArenaFPMintzerDMEppersonALWalkerMSPhase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancerClin Breast Cancer2012122879322154117
   PubMed Web of Science ®Google Scholar
• LinkJSWaismanJRNquyenBJacobsCIBevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancerClin Breast Cancer200771077978318021479
   PubMed Web of Science ®Google Scholar
• MirtschingBCosgriffTHarkerGKeatonMChidiacTMinMA phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancerClin Breast Cancer201111212112821569998
   PubMed Web of Science ®Google Scholar